Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome — SAPHO  

SAPHO Syndrome Clinical Trial

Official title: A Multicenter, Randomized, Double-blind Clinical Trial Evaluating the Efficacy and Safety of Etanercept Versus Placebo in the Treatment of Patients With SAPHO Syndrome

Status Recruiting

Clinical Trial Summary

The study includes adult patients with SAPHO syndrome (ORPHA: 793), meeting the modified classification criteria according to Kahn (2003), with the ineffectiveness of standard treatment (patient's global assessment of the disease on the VAS scale greater than or equal to 4 cm with accompanying pain on the VAS scale greater than or equal to 4 cm) treated with non-steroidal anti-inflammatory drugs in a stable dose for at least 4 weeks and/or classical disease-modifying antirheumatic drugs in stable doses for at least 12 weeks.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• SAPHO Syndrome
• Syndrome

• NCT number: NCT06011889
• Study type: Interventional
• Source: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
• Contact: Jakub Wronski, PhD, MD
• Phone: 22 6880632
• Email: jakub.wronski@spartanska.pl
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: December 13, 2023
• Completion date: October 18, 2028